A pharmaceutical formulation comprising a compound of Formula I wherein: A is an antioxidant of Formula II: and/or reduced form thereof, wherein m comprises an integer from 1 to 3; Y is independently selected from the group consisting of: lower alkyl, lower alkoxy, or two adjacent Y groups, together with carbon atoms to which they are attached, form a following structure of Formula III: and/or reduced form thereof, wherein: R1 and R2 are the same or different and are each independently lower alkyl or lower alkoxy; L is a linker group, comprising: a) a straight or branched hydrocarbon chain optionally substituted by one or more double or triple bond, or ether bond, or ester bond, or C-S, or S-S, or peptide bond; and which is optionally substituted by one or more substituents preferably selected from alkyl, alkoxy, halogen, keto group, amino group; or b) a natural isoprene chain; n is an integer from 1 to 20; and B is a targeting group comprising: a) a Skulachev-ion Sk (Sk + Z -) wherein: Sk is a lipophillic cation or a lipophillic metalloporphyrin, and Z is a pharmaceutically acceptable anion; or b) an amphiphillic zwitterion, in oxidized and/or reduced form in 20% to 100% of 1,2-propylene glycol or 10-30% glycerol, with the proviso that in compound of Formula I, A is not ubiquinone ( e.g., 2-methyl-4,5-dimethoxy-3,6-dioxo-1,4-cyclohexadienyl) or tocopherol or a mimetic of superoxide dismutase or ebselen; when L is divalent decyl, divalent pentyl, or divalent propyl radical and when B is triphenylphosphonium cation. A is an antioxidant of Formula II: and/or reduced form thereof, wherein m comprises an integer from 1 to 3; Y is independently selected from the group consisting of: lower alkyl, lower alkoxy, or two adjacent Y groups, together with carbon atoms to which they are attached, form a following structure of Formula III: and/or reduced form thereof, wherein: R1 and R2 are the same or different and are each independently lower alkyl or lower alkoxy; L is a linker group, comprising: a) a straight or branched hydrocarbon chain optionally substituted by one or more double or triple bond, or ether bond, or ester bond, or C-S, or S-S, or peptide bond; and which is optionally substituted by one or more substituents preferably selected from alkyl, alkoxy, halogen, keto group, amino group; or b) a natural isoprene chain; n is an integer from 1 to 20; and B is a targeting group comprising: a) a Skulachev-ion Sk (Sk + Z -) wherein: Sk is a lipophillic cation or a lipophillic metalloporphyrin, and Z is a pharmaceutically acceptable anion; or b) an amphiphillic zwitterion, R1 and R2 are the same or different and are each independently lower alkyl or lower alkoxy; L is a linker group, comprising: a) a straight or branched hydrocarbon chain optionally substituted by one or more double or triple bond, or ether bond, or ester bond, or C-S, or S-S, or peptide bond; and which is optionally substituted by one or more substituents preferably selected from alkyl, alkoxy, halogen, keto group, amino group; or b) a natural isoprene chain; n is an integer from 1 to 20; and B is a targeting group comprising: a) a Skulachev-ion Sk (Sk + Z -) wherein: Sk is a lipophillic cation or a lipophillic metalloporphyrin, and Z is a pharmaceutically acceptable anion; or b) an amphiphillic zwitterion,